High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy

被引：13

作者：

Huang, Wenrong ^{[1
]}

Li, Jian ^{[2
]}

Li, Honghua ^{[1
]}

Kang, Wenying ^{[2
]}

Bo, Jian ^{[1
]}

Zhao, Yu ^{[1
]}

Gao, Chunji ^{[1
]}

Zhou, Daobin ^{[2
]}

Yu, Li ^{[1
]}

机构：

[1] Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing 100853, Peoples R China

[2] Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

来源：

LEUKEMIA & LYMPHOMA | 2012年 / 53卷 / 12期

关键词：

INTERGROUPE FRANCOPHONE; DEXAMETHASONE; VINCRISTINE; PREDNISONE; PHASE-2; TRIAL;

D O I：

10.3109/10428194.2012.685735

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2507 / 2510

页数：4

共 15 条

[1] Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma [J].

Anagnostopoulos, A ;

Aleman, A ;

Ayers, G ;

Donato, M ;

Champlin, R ;

Weber, D ;

Alexanian, R ;

Giralt, S .

CANCER, 2004, 100 (12) :2607-2612

[2] Phase I/II trial assessing bortezomlb and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma [J].

Berenson, JR ;

Yang, HH ;

Sadler, K ;

Jarutirasarn, SG ;

Vescio, RA ;

Mapes, R ;

Purner, M ;

Lee, SP ;

Wilson, J ;

Morrison, B ;

Adams, J ;

Schenkein, D ;

Swift, R .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :937-944

[3] Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study [J].

Dimopoulos, Meletios A. ;

Mateos, Maria-Victoria ;

Richardson, Paul G. ;

Schlag, Rudolf ;

Khuageva, Nuriet K. ;

Shpilberg, Ofer ;

Kropff, Martin ;

Spicka, Ivan ;

Palumbo, Antonio ;

Wu, Ka Lung ;

Esseltine, Dixie-Lee ;

Liu, Kevin ;

Deraedt, William ;

Cakana, Andrew ;

van de Velde, Helgi ;

San Miguel, Jesus F. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2011, 86 (01) :23-31

[4] International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

[5]

Harousseau JL, 2006, HAEMATOLOGICA, V91, P1498

[6] Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial [J].

Harousseau, Jean-Luc ;

Attal, Michel ;

Avet-Loiseau, Herve ;

Marit, Gerald ;

Caillot, Denis ;

Mohty, Mohamad ;

Lenain, Pascal ;

Hulin, Cyrille ;

Facon, Thierry ;

Casassus, Philippe ;

Michallet, Mauricette ;

Maisonneuve, Herve ;

Benboubker, Lotfi ;

Maloisel, Frederic ;

Petillon, Marie-Odile ;

Webb, Iain ;

Mathiot, Claire ;

Moreau, Philippe .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :4621-4629

[7] Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial [J].

Kim, Hye Jin ;

Yoon, Sung-Soo ;

Lee, Dong Soon ;

Sohn, Sang Kyun ;

Eom, Hyeon Seok ;

Lee, Jung Lim ;

Chung, Joo Seup ;

Kim, Kihyun ;

Suh, Cheolwon ;

Won, Jong Ho ;

Kim, Jin Seok ;

Park, Joon Seong ;

Kang, Hye Jin ;

Seong, Chu Myong ;

Kim, Cheol Soo ;

Lee, Sang Jae ;

Lee, Jae Hoon .

ANNALS OF HEMATOLOGY, 2012, 91 (02) :249-256

[8]

Lee Se Ryeon, 2010, Korean J Hematol, V45, P183, DOI 10.5045/kjh.2010.45.3.183

[9] A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study [J].

Lonial, Sagar ;

Kaufman, Jonathan ;

Tighiouart, Mourad ;

Nooka, Ajay ;

Langston, Amelia A. ;

Heffner, Leonard T. ;

Torre, Claire ;

McMillan, Stephanie ;

Renfroe, Heather ;

Harvey, R. Donald ;

Lechowicz, Mary J. ;

Khoury, H. Jean ;

Flowers, Christopher R. ;

Waller, Edmund K. .

CLINICAL CANCER RESEARCH, 2010, 16 (20) :5079-5086

[10] Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma:: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial [J].

Moreau, P ;

Facon, T ;

Attal, M ;

Hulin, C ;

Michallet, M ;

Maloisel, F ;

Sotto, JJ ;

Guilhot, F ;

Marit, G ;

Doyen, C ;

Jaubert, A ;

Fuzibet, JG ;

François, S ;

Benboubker, L ;

Monconduit, M ;

Voillat, L ;

Macro, M ;

Berthou, C ;

Dorvaux, V ;

Pignon, B ;

Rio, B ;

Matthes, T ;

Casassus, P ;

Caillot, D ;

Najman, N ;

Grosbois, B ;

Bataille, R ;

Harousseau, JL .

BLOOD, 2002, 99 (03) :731-735

← 1 2 →